[go: up one dir, main page]

PE20081456A1 - Anticuerpo monoclonal contra nectina 2 - Google Patents

Anticuerpo monoclonal contra nectina 2

Info

Publication number
PE20081456A1
PE20081456A1 PE2007001348A PE2007001348A PE20081456A1 PE 20081456 A1 PE20081456 A1 PE 20081456A1 PE 2007001348 A PE2007001348 A PE 2007001348A PE 2007001348 A PE2007001348 A PE 2007001348A PE 20081456 A1 PE20081456 A1 PE 20081456A1
Authority
PE
Peru
Prior art keywords
nectin
necl
ferm
antibody
monoclonal antibody
Prior art date
Application number
PE2007001348A
Other languages
English (en)
Inventor
Shuji Sato
Tsutomu Oshima
Tomofumi Kurokawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44083820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081456(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2006/320429 external-priority patent/WO2007043635A1/ja
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20081456A1 publication Critical patent/PE20081456A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL CONTRA LA PROTEINA NECTINA-2; QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS REPRESENTADA POR SEC ID NO: 1 (NECTINA 2a) O SEC ID NO: 3 (NECTINA 2d), O SU PEPTIDO PARCIAL; DONDE LA REGION CONSTANTE DE DICHO ANTICUERPO PERTENECE AL A SUBCLASE DE IgG1 HUMANA. TAMBIEN SE REFIERE A UNA CELULA DE HIBRIDOMA QUE ES CAPAZ DE PRODUCIR DICHO ANTICUERPO Y ESTA REPRESENTADA POR NECL-803-2 (FERM BP-10417), NECL-244-3 (FERM BP-10423), NECL-503-1 (FERM BP-10424), ENTRE OTROS Y UNA COMPOSICION FARMACEUTICA. ESTE ANTICUERPO PRESENTA ACTIVIDAD INHIBITORIA DE LA UNION TRANS DE NECTINA 2/NECTINA 3 O NECTINA 2/NECTINA 2, POR LO QUE ES UTIL COMO UN AGENTE DE DIAGNOSTICO Y EN EL TRATAMIENTO DE CANCER, INHIBIENDO EL CRECIMIENTO DE CELULAS CANCEROSAS, EN ESPECIAL EN EL TRATAMIENTO DEL CANCER DE MAMA
PE2007001348A 2006-10-06 2007-10-04 Anticuerpo monoclonal contra nectina 2 PE20081456A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2006/320429 WO2007043635A1 (ja) 2005-10-07 2006-10-06 癌の予防・治療剤
ARP070101453A AR060362A1 (es) 2005-10-07 2007-04-04 Agente para prevenir / tratar el cancer
JP2007100876 2007-04-06

Publications (1)

Publication Number Publication Date
PE20081456A1 true PE20081456A1 (es) 2008-11-27

Family

ID=44083820

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001348A PE20081456A1 (es) 2006-10-06 2007-10-04 Anticuerpo monoclonal contra nectina 2

Country Status (21)

Country Link
US (1) US20100008928A1 (es)
EP (1) EP2067791A4 (es)
JP (1) JPWO2008044754A1 (es)
KR (1) KR20090078339A (es)
CN (1) CN101541834A (es)
AR (1) AR063153A1 (es)
AU (1) AU2007307536A1 (es)
BR (1) BRPI0717024A2 (es)
CA (1) CA2666249A1 (es)
CL (1) CL2007002879A1 (es)
CO (1) CO6190538A2 (es)
EC (1) ECSP099276A (es)
IL (1) IL197389A0 (es)
MA (1) MA30816B1 (es)
MX (1) MX2009003126A (es)
NO (1) NO20091783L (es)
PE (1) PE20081456A1 (es)
RU (1) RU2009117237A (es)
TN (1) TN2009000090A1 (es)
TW (1) TW200823235A (es)
WO (1) WO2008044754A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012092374A2 (en) * 2010-12-31 2012-07-05 Short Jay M Express humanization of antibodies
DK2740794T3 (en) * 2011-08-04 2018-06-14 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
EP3202419A1 (en) * 2012-06-06 2017-08-09 OncoMed Pharmaceuticals, Inc. Pvrig binding agents that modulate the hippo pathway and uses thereof
WO2014069682A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2014069681A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
PL3653221T3 (pl) 2015-02-19 2022-12-19 Compugen Ltd. Przeciwciała anty-pvrig i sposoby ich zastosowania
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
RU2765410C2 (ru) 2016-11-30 2022-01-28 Онкомед Фармасьютикалс, Инк. Способы лечения рака, включающие связывающие tigit агенты
US11225523B2 (en) 2017-06-01 2022-01-18 Compugen Ltd. Triple combination antibody therapies
AU2019306628B2 (en) 2018-07-20 2024-11-14 Surface Oncology, LLC Anti-CD112R compositions and methods
CN118878685A (zh) * 2019-01-13 2024-11-01 耶路撒冷希伯来大学伊森姆研究发展有限公司 特异性针对人类连接蛋白-2的抗体
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
BR112023014128A2 (pt) 2021-01-15 2023-10-31 Seagen Inc Conjugados de anticorpo-fármaco imunomodulatórios
JP2024506300A (ja) 2021-02-03 2024-02-13 シージェン インコーポレイテッド 免疫刺激化合物及びコンジュゲート体
WO2023161943A1 (en) * 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies against nectin-2 and drug conjugates thereof
CA3252067A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory Antibody-Drug Conjugates
CA3262320A1 (en) 2022-08-03 2024-02-08 Regents Of The University Of Minnesota Anti-PD-L1 Conjugates - Immunostimulating Drugs
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1999063063A1 (en) 1998-06-03 1999-12-09 Northwestern University Cellular proteins which mediate herpesvirus entry
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
DE19852800C1 (de) 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
US20030022279A1 (en) * 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
MXPA03002479A (es) 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
EP1402058A4 (en) 2001-06-05 2006-02-01 Exelixis Inc DGKS AS P53 PATH MODIFICATORS AND METHOD OF USE
CA2449303C (en) 2001-06-06 2014-10-14 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20030084468A1 (en) 2001-09-05 2003-05-01 Economides Aris N. Methods of expressing transgenes
CA2481507A1 (en) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JPWO2005097204A1 (ja) * 2004-04-09 2008-02-28 武田薬品工業株式会社 癌の予防・治療剤

Also Published As

Publication number Publication date
JPWO2008044754A1 (ja) 2010-02-18
MA30816B1 (fr) 2009-10-01
BRPI0717024A2 (pt) 2014-03-11
CL2007002879A1 (es) 2008-06-27
WO2008044754A1 (en) 2008-04-17
EP2067791A1 (en) 2009-06-10
IL197389A0 (en) 2011-08-01
NO20091783L (no) 2009-07-01
CO6190538A2 (es) 2010-08-19
EP2067791A4 (en) 2009-11-25
TN2009000090A1 (en) 2010-08-19
RU2009117237A (ru) 2010-11-20
MX2009003126A (es) 2009-04-06
CN101541834A (zh) 2009-09-23
US20100008928A1 (en) 2010-01-14
ECSP099276A (es) 2009-06-30
KR20090078339A (ko) 2009-07-17
AU2007307536A1 (en) 2008-04-17
AU2007307536A2 (en) 2009-04-30
AR063153A1 (es) 2008-12-30
TW200823235A (en) 2008-06-01
CA2666249A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
PE20081456A1 (es) Anticuerpo monoclonal contra nectina 2
CO2020014727A2 (es) Anticuerpo anti proteína reguladora de señales alfa sirpαlfa
AR062065A1 (es) Anticuerpo humanizado
PE20110561A1 (es) Anticuerpos contra il-6
EA201991099A1 (ru) Антитела против cd73 и их применение
CO6180466A2 (es) Composiciones y metodos para diagnosticar y tratar cancer
MX377317B (es) Compuestos de hormona de crecimiento humana recombinante unidos a peg.
BRPI0514199A (pt) método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7
BRPI0306973B8 (pt) anticorpos anti-igf-ir, seu método de produção e seus usos, hibridoma murino, ácido nucléico isolado, vetor, composição, kit ou conjunto, e método diagnóstico in vitro de doenças induzidas por uma superexpressão ou uma subexpressão do receptor igf-ir
CY1112241T1 (el) Θραυσματα πεπτιδιου για διεγερση συνθεσης πρωτεϊνων εξωκυτταρικης μητρας
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
CO6180469A2 (es) Anticuerpos anti-epha2
MY183804A (en) Humanized anti-factor d antibodies
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
AR069393A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
EP4349360A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
RU2010108429A (ru) Регуляторы ммр-9 и их применение
PE20080187A1 (es) Agonistas receptores de eritropoietina

Legal Events

Date Code Title Description
FD Application declared void or lapsed